Proximagen Neuroscience plc
(the "Company")
Change of Nomad and Broker
31
January 2008 - Proximagen Neuroscience plc (AIM:
PRX), the drug discovery and development company
focused on neurodegenerative diseases, is
pleased to announce the appointment of Canaccord
Adams Limited ('Canaccord Adams') as its
Nominated Adviser and Broker with immediate
effect.
For more information please contact:
Proximagen Neuroscience plc
020 7848 6938
Kenneth Mulvany, Chief Executive Officer
James Hunter, Finance Director
Buchanan Communications 020 7466 5000
Tim Anderson / Mary-Jane Johnson / Catherine
Breen
Canaccord Adams Limited (Nominated Adviser
and Broker) 020 7050 6500
Mark Williams
